<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111551</url>
  </required_header>
  <id_info>
    <org_study_id>14-0614</org_study_id>
    <nct_id>NCT02111551</nct_id>
  </id_info>
  <brief_title>Phase I Nicotinic Agonist Treatment Trial for Autism</brief_title>
  <official_title>Phase I Nicotinic Agonist Treatment Trial for Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A
      [3-(2,4-dimethoxybenzylidene) anabaseine] may have positive effects on mental focus and may
      help us to find new types of treatment for autism spectrum disorder. Subjects will come in
      for a screening visit and three more drug visits. There will be at least one week between
      each drug visit to allow the drug to be eliminated from your system completely. During each
      drug visit subjects will receive either a placebo (a capsule that looks like medicine but is
      not real), 75 mg of DMXB-A, or 150 mg of DMXB-A. During the drug day vital signs and well
      being will be monitored by the study physician. Subjects will complete some paper and pencil
      tasks to test memory, attention, speed, and problem solving, some rating scales and
      questionnaires, and the study team will record brain wave patterns with an
      electroencephalogram (EEG) .
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficult to find participants and no funding
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between drug and placebo on theTotal Scale Score on the repeatable Battery for the Assessment of neuropsychological Status at 2 hours after administration</measure>
    <time_frame>2 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference between drug and placebo on the CPT at 30 minutes after administration</measure>
    <time_frame>30 minutes after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference between the P50 auditory evoked potential test/conditioning ratio 1 hour after administration</measure>
    <time_frame>1 hour after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference between placebo and drug on the Social Responsiveness scale 2 hours after administration</measure>
    <time_frame>2 hours after drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>DMXB-A 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMXB-A 75 mg dose followed by a second dose of 37.5 mg at 2 hours to maintain the blood level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMXB-A 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMXB-A 150 mg followed by a second dose of 75 mg at 2 hours to maintain the blood level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator dose followed by a second placebo dose at 2 hours to maintain blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMXB-A 150 mg</intervention_name>
    <arm_group_label>DMXB-A 75 mg</arm_group_label>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>DMXB-A 75 mg</arm_group_label>
    <arm_group_label>DMXB-A 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMXB-A 75 mg</intervention_name>
    <arm_group_label>DMXB-A 150 mg</arm_group_label>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-50

          -  meet DSM-5 criteria for Autism Spectrum Disorder, Levels 1 or 2, as defined by Autism
             Diagnostic Observation Schedule

          -  non-smoking persons

          -  in good health

        Exclusion Criteria:

          -  persons with estimated verbal and nonverbal IQ &lt; 70.

          -  abuse of other substances.

          -  Persons not sufficiently fluent in English to permit testing

          -  those with history of severe head injury

          -  Fragile X Syndrome

          -  Rett Syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Freedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008 Aug;165(8):1040-7. doi: 10.1176/appi.ajp.2008.07071135. Epub 2008 Apr 1.</citation>
    <PMID>18381905</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Nicotinic agonist</keyword>
  <keyword>Cognition</keyword>
  <keyword>P50</keyword>
  <keyword>Alpha 7</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-(2,4-dimethoxybenzylidene)anabaseine</mesh_term>
    <mesh_term>Nicotinic Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

